NASDAQ:NCNA

NuCana Stock Forecast, Price & News

$4.29
-0.05 (-1.15 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.11
Now: $4.29
$4.37
50-Day Range
$4.31
MA: $5.03
$5.70
52-Week Range
$4.02
Now: $4.29
$7.83
Volume176,999 shs
Average Volume511,688 shs
Market Capitalization$208.04 million
P/E RatioN/A
Dividend YieldN/A
Beta0.92
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
NuCana logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NCNA
CUSIPN/A
Phone44-0-13-1357-1111
Employees27
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.52 per share

Profitability

Net Income$-27,340,000.00

Miscellaneous

Market Cap$208.04 million
Next Earnings Date5/18/2021 (Estimated)
OptionableNot Optionable

Headlines

Form 6-K NuCana plc For: Apr 12 - StreetInsider.com
April 12, 2021 |  streetinsider.com
NuCana plc (NASDAQ:NCNA) Short Interest Up 55.7% in March
March 31, 2021 |  americanbankingnews.com
NuCana (NASDAQ:NCNA) Receives "Buy" Rating from William Blair
March 30, 2021 |  americanbankingnews.com
Circling Back On NuCana Stock - Seeking Alpha
March 3, 2021 |  seekingalpha.com
NuCana to Participate in Three Upcoming Investor Conferences
February 25, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.54 out of 5 stars

Medical Sector

466th out of 2,025 stocks

Pharmaceutical Preparations Industry

223rd out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$4.29
-0.05 (-1.15 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NCNA News and Ratings via Email

Sign-up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NuCana (NASDAQ:NCNA) Frequently Asked Questions

Is NuCana a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NuCana stock.
View analyst ratings for NuCana
or view top-rated stocks.

What stocks does MarketBeat like better than NuCana?

Wall Street analysts have given NuCana a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NuCana wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting NuCana?

NuCana saw a increase in short interest in March. As of March 15th, there was short interest totaling 119,600 shares, an increase of 55.7% from the February 28th total of 76,800 shares. Based on an average trading volume of 546,300 shares, the short-interest ratio is presently 0.2 days.
View NuCana's Short Interest
.

When is NuCana's next earnings date?

NuCana is scheduled to release its next quarterly earnings announcement on Tuesday, May 18th 2021.
View our earnings forecast for NuCana
.

How were NuCana's earnings last quarter?

NuCana plc (NASDAQ:NCNA) announced its quarterly earnings data on Thursday, March, 4th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.11.
View NuCana's earnings history
.

How has NuCana's stock price been impacted by Coronavirus (COVID-19)?

NuCana's stock was trading at $6.34 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NCNA stock has decreased by 32.3% and is now trading at $4.29.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NCNA?

6 brokerages have issued 1-year target prices for NuCana's stock. Their forecasts range from $10.00 to $22.00. On average, they anticipate NuCana's share price to reach $17.50 in the next year. This suggests a possible upside of 307.9% from the stock's current price.
View analysts' price targets for NuCana
or view top-rated stocks among Wall Street analysts.

Who are NuCana's key executives?

NuCana's management team includes the following people:
  • Mr. Hugh Stephen Griffith, Founder, CEO & Exec. Director (Age 53, Pay $1.26M)
  • Mr. Donald Munoz, Chief Financial Officer (Age 52)
  • Prof. Christopher B. Wood, Chief Medical Officer (Age 75, Pay $113.78k)
  • Mr. David Harrison, Head of Translational Medicine
  • Ms. Theresa Bruce, Sr. VP of Clinical Operations
  • Ms. Elisabeth Oelmann, Sr. VP of Medical & Clinical Devel.
  • Martin Quinn, Company Sec.

Who are some of NuCana's key competitors?

What other stocks do shareholders of NuCana own?

When did NuCana IPO?

(NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

How do I buy shares of NuCana?

Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $4.29.

How much money does NuCana make?

NuCana has a market capitalization of $208.04 million. The company earns $-27,340,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does NuCana have?

NuCana employs 27 workers across the globe.

What is NuCana's official website?

The official website for NuCana is www.nucana.com.

Where are NuCana's headquarters?

NuCana is headquartered at 3 Lochside Way, Edinburgh X0, EH12 9DT.

How can I contact NuCana?

NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The company can be reached via phone at 44-0-13-1357-1111 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.